scholarly journals VISUAL MEDIAL TEMPORAL ATROPHY SCALES IN CLINICIAN PRACTICE

2021 ◽  
Author(s):  
Karen Socher ◽  
Douglas Nunes ◽  
Deborah Lopes ◽  
Artur Coutinho ◽  
Daniele Faria ◽  
...  
Keyword(s):  
Medial Temporal Lobe ◽  
Screening Tool ◽  
Cognitive Status ◽  
Temporal Region ◽  
Medial Temporal Lobe Atrophy ◽  
Sociodemographic Data ◽  
Preclinical Ad ◽  
Moderate Sensitivity ◽  
Lobe Atrophy ◽  
Clinician Practice

Background: Visual atrophy scales from the medial temporal region are auxiliary biomarker methods in Alzheimer’s Disease(AD).They may correlated with progression from preclinical to clinical AD. Objective: We aimed to compare medial temporal lobe atrophy (MTA) and entorhinal cortex atrophy (ERICA) scales for magnetic resonance image as a useful tool for probable AD diagnosis and evaluate their accuracy, sensitivity and specificity, regarding clinical diagnosis and 11C-PIB-PET. Methods: 2 neurologists blinded to diagnosis classified 113 adults (over 65y) through MTA and ERICA scales and correlated with sociodemographic data, amyloid brain cortical burden through the 11C-PIB-PET and clinical cognitive status, divided into 30 cognitive unimpaired (CU) individuals, 52 MCI and 31 dementia compatible with AD (DCAD). Results: Inter-rater reliability of these atrophy scales was excellent (0.8- 1) by Cohen analysis. CU group had significantly lower MTA scores (median value 0) than ERICA (median value 1)for both hemispheres. 11C-PIB-PET was positive in 45% of the whole sample. In MCI and DCAD groups, ERICA depicted greater sensitivity and MTA greater specificity. Accuracy was under 70% for both scores in all clinical groups. Conclusion: Our study achieved a moderate sensitivity for ERICA score and could be a better screening tool for DCAD or MCI than MTA score. But, none of them could be considered a useful biomarker in preclinical AD.

scholarly journals Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid

2019 ◽  
Vol 11 (1) ◽  
Author(s):  
Anna Rosenberg ◽  
Alina Solomon ◽  
Vesna Jelic ◽  
Göran Hagman ◽  
Nenad Bogdanovic ◽  
...  
Keyword(s):  
Medial Temporal Lobe ◽  
Predictive Performance ◽  
Csf Biomarkers ◽  
Memory Clinic ◽  
Alzheimer Type ◽  
Normal Range ◽  
Medial Temporal Lobe Atrophy ◽  
Dementia Risk ◽  
Β Amyloid ◽  
Lobe Atrophy

Abstract Background Determination of β-amyloid (Aβ) positivity and likelihood of underlying Alzheimer’s disease (AD) relies on dichotomous biomarker cut-off values. Individuals with mild cognitive impairment (MCI) and Aβ within the normal range may still have a substantial risk of developing dementia, primarily of Alzheimer type. Their prognosis, as well as predictors of clinical progression, are not fully understood. The aim of this study was to explore the associations of cerebrospinal fluid (CSF) biomarkers (Aβ42, total tau, phosphorylated tau) and other characteristics, including modifiable vascular factors, with the risk of progression to dementia among patients with MCI and normal CSF Aβ42. Methods Three hundred eighteen memory clinic patients with CSF and clinical data, and at least 1-year follow-up, were included. Patients had normal CSF Aβ42 levels based on clinical cut-offs. Cox proportional hazard models with age as time scale and adjusted for sex, education, and cognition (Mini-Mental State Examination) were used to investigate predictors of progression to dementia and Alzheimer-type dementia. Potential predictors included CSF biomarkers, cognitive performance (verbal learning and memory), apolipoprotein E (APOE) ε4 genotype, medial temporal lobe atrophy, family history of dementia, depressive symptoms, and vascular factors, including the Cardiovascular Risk Factors, Aging and Dementia (CAIDE) risk score. Predictive performance of patient characteristics was further explored with Harrell C statistic. Results Lower normal Aβ42 and higher total tau and phosphorylated tau were associated with higher dementia risk, and the association was not driven by Aβ42 values close to cut-off. Additional predictors included poorer cognition, APOE ε4 genotype, higher systolic blood pressure, and lower body mass index, but not the CAIDE dementia risk score. Aβ42 individually and in combination with other CSF biomarkers improved the risk prediction compared to age and cognition alone. Medial temporal lobe atrophy or vascular factors did not increase the predictive performance. Conclusions Possibility of underlying AD pathology and increased dementia risk should not be ruled out among MCI patients with CSF Aβ42 within the normal range. While cut-offs may be useful in clinical practice to identify high-risk individuals, personalized risk prediction tools incorporating continuous biomarkers may be preferable among individuals with intermediate risk. The role of modifiable vascular factors could be explored in this context.

scholarly journals False positives to confusable objects predict medial temporal lobe atrophy

Hippocampus ◽  
2013 ◽  
Vol 23 (9) ◽  
pp. 832-841 ◽  
Author(s):  
Sasa L. Kivisaari ◽  
Andreas U. Monsch ◽  
Kirsten I. Taylor
Keyword(s):  
Temporal Lobe ◽  
Medial Temporal Lobe ◽  
False Positives ◽  
Medial Temporal Lobe Atrophy ◽  
Lobe Atrophy

Medial temporal lobe atrophy, but not CSF biomarkers, correlates with cognitive impairment in Alzheimer's disease

2021 ◽  
Vol 429 ◽  
pp. 119059
Author(s):  
Edoardo Barvas ◽  
Chiara Monaldini ◽  
Roberto Frusciante ◽  
Mirco Volpini ◽  
Beatrice Viti ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Temporal Lobe ◽  
Medial Temporal Lobe ◽  
Csf Biomarkers ◽  
Medial Temporal Lobe Atrophy ◽  
Lobe Atrophy

scholarly journals P3-418: MEDIAL TEMPORAL LOBE ATROPHY IN AMYLOID POSITIVE COGNITIVE DECLINE

2019 ◽  
Vol 15 ◽  
pp. P1116-P1117
Author(s):  
Jonas Alexander Jarholm ◽  
Lene Pålhaugen ◽  
Tormod Fladby ◽  
Per Selnes
Keyword(s):  
Cognitive Decline ◽  
Temporal Lobe ◽  
Medial Temporal Lobe ◽  
Medial Temporal Lobe Atrophy ◽  
Lobe Atrophy

Combining Visual Rating Scales for Medial Temporal Lobe Atrophy and Posterior Atrophy to Identify Amnestic Mild Cognitive Impairment from Cognitively Normal Older Adults: Evidence Based on Two Cohorts

2020 ◽  
Vol 77 (1) ◽  
pp. 323-337
Author(s):  
Can Sheng ◽  
Yu Sun ◽  
Min Wang ◽  
Xiaoni Wang ◽  
Yi Liu ◽  
...  
Keyword(s):  
Medial Temporal Lobe ◽  
Rating Scales ◽  
Rating Scale ◽  
Discriminative Power ◽  
Medial Temporal Lobe Atrophy ◽  
Cognitively Normal ◽  
Visual Rating ◽  
Visual Rating Scale ◽  
Visual Assessments ◽  
Lobe Atrophy

Background: Visual rating scales for medial temporal lobe atrophy (MTA) and posterior atrophy (PA) have been reported to be useful for Alzheimer’s disease diagnosis in routine clinical practice. Objective: To investigate the efficacy of combined MTA and PA visual rating scales to discriminate amnestic mild cognitive impairment (aMCI) patients from healthy controls. Methods: This study included T1-weighted MRI images from two different cohorts. In the first cohort, we recruited 73 patients with aMCI and 48 group-matched cognitively normal controls for training and validation. Visual assessments of MTA and PA were carried out for each participant. Global gray matter volume and density were estimated using voxel-based morphometry analysis as the objective reference. We investigated the discriminative power of a single visual rating scale and the combination of the MTA and PA rating scales for identifying aMCI. The second cohort, consisting of 33 aMCI patients and 45 controls, was used to verify the reliability of the visual assessments. Results: Compared with the single visual rating scale, the combination of the MTA and PA exhibited the best discriminative power, with an AUC of 0.818±0.041, which was similar to the diagnostic accuracy of the gray matter volumetric measures. The discriminative power of the combined MTA and PA was verified in the second cohort (AUC 0.824±0.058). Conclusion: The combined MTA and PA rating scales demonstrated practical diagnostic value for distinguishing aMCI patients from controls, suggesting its potential to serve as a convenient and reproducible method to assess the degree of atrophy in clinical settings.

scholarly journals Modified Visual Magnetic Resonance Rating Scale for Evaluation of Patients with Forgetfulness

2018 ◽  
Vol 46 (1) ◽  
pp. 71-78
Author(s):  
Betul Z. Yalciner ◽  
Melek Kandemir ◽  
Sencan Taskale ◽  
Savas M. Tepe ◽  
Devrim Unay
Keyword(s):  
Medial Temporal Lobe ◽  
Rating Scale ◽  
Daily Practice ◽  
Medial Temporal Lobe Atrophy ◽  
Cranial Mri ◽  
The Mean ◽  
Depression Scales ◽  
State Examination ◽  
Depressive Patients ◽  
Lobe Atrophy

AbstractBackgroundAs cognitive impairment increases with age, sulcal atrophy (SA) and the enlargement of the ventricles also increase. Considering the measurements on the previously proposed visual scales, a new scale is proposed in this study that allows us to evaluate the atrophy, white matter hyperintensities (WMHs), basal ganglia infarct (BGI), and infratentorial infarct (ITI) together. Our aim of this study is to propose a practical and standardized MRI for the clinicians to be used in daily practice.MethodsA total of 97 patients older than 60 years and diagnosed with depression or Alzheimer’s disease (AD) are included. Cranial MRI, Mini Mental State Examination (MMSE), detailed neuropsychometric tests, and depression scales are applied to all patients. The SA, ventricular atrophy (VA), medial temporal lobe atrophy (MTA), periventricular WMH (PWMH), subcortical WMH (SCWMH), BGI, and ITI are scored according to the scale. The total score is also recorded.ResultsThe average age of the patients was 74.53, and the mean MMSE score was 22.7 in the degenerative group and 27.8 in the non-degenerative group. Among the patients, 50 were diagnosed with AD. All parameters significantly increased with age. In the degenerative group, SA, VA, MTA, PWMH, SCWMH, and total scores were found to be significantly higher. Sensitivities of VA, PWMH, SCWMH, and total scores, as well as both sensitivity and specificities of MTA score, were observed to be high. When they were combined, sensitivities and specificities were found to be high.ConclusionThe scale is observed to be predictive in discriminating degenerative and non-degenerative processes. This discrimination is important, particularly in depressive patients complaining of forgetfulness.

Sign in / Sign up

Export Citation Format

Share Document